taxanes + gemcitabine + pemetrexed

This regimen is a **combination chemotherapy protocol** consisting of three drugs: taxanes (a class of microtubule inhibitors, commonly including paclitaxel or docetaxel), gemcitabine (a nucleoside analog antimetabolite), and pemetrexed (a multi-targeted antifolate antimetabolite). Each agent disrupts critical pathways for cancer cell proliferation: taxanes inhibit microtubule depolymerization and block mitosis; gemcitabine incorporates into DNA and inhibits DNA synthesis; pemetrexed inhibits several folate-dependent enzymes essential for the synthesis of nucleotide precursors required for DNA replication and cell division. This combination is explored or used primarily for the treatment of non-small cell lung cancer (NSCLC) and other advanced malignancies where multi-agent chemotherapy is indicated. The regimen is administered intravenously.